ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Adjuvant

Also written as “Monovalent Avian Influenza VLP (H5N1); Adjuvant”, “Matrix-M2 Adjuvant (25μg)” and “Matrix-M2 Adjuvant (50μg)”.

Its studies are mostly in Influenza, Human · Herpes Simplex · Herpes Zoster · Malaria · Respiratory Syncytial Virus Infections, led by 11 companies.

Drug pageAdjuvant: every studyMany companies study it; this page follows only the 15 they lead. All 21 studies, academic ones too, with its approvals and label.
Furthest: phase 2, since Apr 11, 201415 company-led studies, 3 open or runningNext primary completion: Jan 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genocea Biosciencesits history only30 open or runningphase 2since Apr 11, 2014Nov 19, 2013none ahead
BioTech Toolsits history only20 open or runningphase 2since Dec 7, 2011Apr 20, 2010none ahead
Novavaxits history only20 open or runningphase 1since May 2, 2012May 2, 2012none ahead
Colby Pharmaceuticalits history only10 open or runningphase 1since Apr 15, 2008Apr 15, 2008none ahead
Guangzhou Patronus Biotechits history only11 open or runningphase 1since May 28, 2024May 28, 2024none ahead
Immune Targeting Systemsits history only10 open or runningphase 1since Oct 3, 2012Oct 3, 2012none ahead
MAXVAX Biotechnology Limited Liabilityits history only10 open or runningphase 1since Nov 16, 2022Nov 16, 2022none ahead
Medigen Vaccine Biologicsits history only10 open or runningphase 2since Apr 27, 2015Apr 27, 2015none ahead
Sanofiits history only10 open or runningphase 1since Jun 25, 2020Jun 25, 2020none ahead
Serum Institute of India Pvt.its history only11 open or runningphase 2since Aug 12, 2025Aug 12, 2025Nov 2027phase 2 · NCT07147400
Yikang Biotech (Suzhou)11 open or runningphase 1since Sep 1, 2026Sep 1, 2026Jan 22, 2027phase 1 · NCT07807449

Also a collaborator on its studies: Yantai Patronus Biotech.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Yikang Biotech (Suzhou) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 1, 2026First study: phase 1 study in Respiratory Syncytial Virus (RSV)First studyNCT07807449 · 128 planned · China

Ahead

  1. Jan 22, 2027Primary completion: phase 1 study in Respiratory Syncytial Virus (RSV)NCT07807449

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Yikang Biotech (Suzhou) leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07807449Respiratory Syncytial Virus (RSV) · China1Not yet recruitingJan 22, 2027128

How it is read

Names in the registry

  • “Monovalent Avian Influenza VLP (H5N1); Adjuvant”, 6 entries
  • “Matrix-M2 Adjuvant (25μg)”, 2 entries
  • “Matrix-M2 Adjuvant (50μg)”, 2 entries
  • “Matrix-M2 Adjuvant (75μg)”, 2 entries
  • “Low dose adjuvant”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.